Prescription ·Strong evidence ·Reviewed May 2026
Glyburide (also known as glibenclamide) is a second-generation sulfonylurea used for glycemic control in type 2 diabetes. It is one of the more potent sulfonylureas and carries a higher risk of hypoglycemia compared to glipizide and glimepiride, particularly in elderly patients and those with renal impairment.
The bottom line
Evidence rating strong. Most-documented uses: lowers hba1c by 1.0–2.0%, potent insulin secretagogue effect, low cost and wide availability. 10 sources indexed (2008–2025), with 8 interaction records on file.
Core mechanism
Binds to sulfonylurea receptor 1 (SUR1) on pancreatic beta cells, blocking ATP-sensitive potassium channels. This causes membrane depolarization, opening of voltage-gated calcium channels, and subsequent insulin secretion. Glyburide also has extrapancreatic effects, including enhanced peripheral glucose utilization and reduced hepatic glucose output.
Take with breakfast or the first main meal. Micronized tablets are not bioequivalent to conventional tablets.
Glyburide is a potent sulfonylurea with high hypoglycemia risk. Adding berberine's AMPK-mediated glucose lowering significantly increases this risk.
Recommendation: Use extreme caution. Glyburide already has the highest hypoglycemia risk among sulfonylureas. Berberine should only be added with close medical supervision and glucose monitoring.
Berberine HCl has clinically measurable glucose-lowering activity. Glyburide is a sulfonylurea with a relatively high hypoglycemia risk, and the combination can lower glucose more than expected. Older adults and people with reduced kidney function are especially vulnerable.
Recommendation: Avoid adding Berberine HCl to glyburide unless your prescriber is supervising glucose monitoring. Check glucose more frequently when starting or stopping Berberine HCl, and have a plan for treating low blood sugar.
Vanadium has insulin-like effects and has improved glucose metabolism in small human studies. Glyburide is a longer-acting sulfonylurea with a higher hypoglycemia burden than some alternatives, so vanadium may further increase the risk of severe or prolonged low blood sugar.
Recommendation: Avoid vanadium while taking glyburide unless your prescriber specifically recommends it and plans glucose monitoring. Be especially cautious with kidney disease, older age, missed meals, alcohol, or exercise changes. Seek urgent care for severe, recurrent, or hard-to-correct hypoglycemia.
Chromium and glyburide both lower blood glucose by different mechanisms. Glyburide is the longest-acting sulfonylurea on the US market and already carries the highest hypoglycemia risk in its class. Adding chromium, which improves insulin sensitivity, can produce prolonged hypoglycemia (especially overnight) in older adults and in anyone with reduced kidney function.
Recommendation: Avoid starting chromium on glyburide unless your prescriber agrees. If you do combine them, monitor fasting and bedtime glucose closely for the first month and ask whether glyburide should be reduced or switched to a shorter-acting sulfonylurea.
Alpha-lipoic acid improves insulin sensitivity and has been reported to trigger insulin autoimmune syndrome (Hirata syndrome) with severe spontaneous hypoglycemia. Glyburide is the longest-acting sulfonylurea and already carries the highest hypoglycemia risk in its class. The combination is particularly hazardous in older adults and patients with renal impairment, where glyburide and its active metabolites accumulate.
Recommendation: Avoid starting ALA on glyburide unless your prescriber agrees and arranges close monitoring. If you do combine them, check fasting and bedtime glucose for at least 4 weeks and seek urgent care for repeated unexplained lows.
Fenugreek extracts lower fasting glucose and HbA1c in type 2 diabetes meta-analyses. Glyburide is the longest-acting US sulfonylurea and already carries the highest hypoglycemia risk in its class, especially in older adults and patients with renal impairment. Adding fenugreek can produce prolonged, sometimes severe lows.
Recommendation: Avoid starting fenugreek on glyburide unless your prescriber agrees and arranges close monitoring. If you do combine them, check fasting and bedtime glucose for at least 4 weeks and ask whether glyburide should be switched to a shorter-acting agent.
A 6-month RCT in 59 patients found that adding silymarin 200 mg three times daily to glyburide improved HbA1c and postprandial glucose more than glyburide alone. Silymarin is a weak CYP2C9 inhibitor in vitro and reduces fasting glucose independently. The combination meaningfully amplifies glyburide's hypoglycemic effect, and glyburide already carries the highest hypoglycemia risk among sulfonylureas, especially in older adults and renal impairment.
Recommendation: Tell your prescriber before adding milk thistle on glyburide. Monitor fasting and bedtime glucose for at least 4 weeks and ask whether your glyburide dose should be reduced. Avoid the combination entirely if you have CKD or are over 75.
Quercetin inhibits CYP2C9 in human studies. Glyburide is metabolized by CYP2C9 (and CYP3A4) and is the longest-acting US sulfonylurea with the highest hypoglycemia risk in its class. Concentrated quercetin supplements can raise glyburide exposure and prolong its hypoglycemic effect, particularly in older adults and patients with renal impairment.
Recommendation: Avoid concentrated quercetin supplements (>500 mg/day) on glyburide unless your prescriber agrees. Dietary quercetin from foods is generally fine. If you take a supplement, monitor fasting and bedtime glucose for the first 4 weeks and discuss whether glyburide should be reduced.
Numbered references. Citations throughout the page link here.
Alsubaiei AAK, Alharran AM, Alfailakawi AK et al.. Glibenclamide in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2025
Oliveira MM, Andrade KFO, Lima GHS et al.. Metformin versus glyburide in treatment and control of gestational diabetes mellitus: a systematic review with meta-analysis. Einstein (Sao Paulo, Brazil). 2022
Guo L, Ma J, Tang J et al.. Comparative Efficacy and Safety of Metformin, Glyburide, and Insulin in Treating Gestational Diabetes Mellitus: A Meta-Analysis. Journal of diabetes research. 2019
Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. The Annals of pharmacotherapy. 2008
Feng X, Zhang T, Wang N et al.. Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial. Stroke and vascular neurology. 2024
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack